IBM to Acquire Cyber Security Specialist Trusteer

ibm-logo-on-wall
IBM will acquire Trusteer for an undisclosed amount.

IBM will form a cyber security laboratory in Israel as part of the agreement, focusing on threats such as malware and financial fraud, in addition to its existing facilities.

Trusteer has offices in Tel Aviv and Boston, with a large bank client base already. IBM sees the acquisition as expanding its commitment to cloud-delivered software and services.

"Trusteer's expertise and superior technology in enterprise endpoint defense and advanced malware prevention will help our clients across all industries address the constantly evolving threats they are facing," says Brendan Hannigan, general manager in the Security Systems Division at IBM. "Together with IBM's capabilities in advanced threat detection, analysis and remediation, we will now be able to offer our clients several additional layers of defense against sophisticated attackers."

The terms of the deal were not disclosed.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Systematic tools gain favor in fixed income

Automation is enabling systematic strategies in fixed income that were previously reserved for equities trading. The tech gap between the two may be closing, but differences remain.

Why recent failures are a catalyst for DLT’s success

Deutsche Bank’s Mathew Kathayanat and Jie Yi Lee argue that DLT's high-profile failures don't mean the technology is dead. Now that the hype has died down, the path is cleared for more measured decisions about DLT’s applications.

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here